Our sponsors are fundamental to the success of the IOIS Congress and once again we’d like to extend our special thanks to all of our sponsors. Without them we would not be able to organize the congress.
Satellite Symposium by ALIMERA SCIENCES
Thursday, June 26, 2025 - 13:15-14:05 - Gavea B
Thursday, June 26, 2025 - 13:15-14:05 - Gavea B
Traffic Lights in NIU-PS – An EU expert user guideline on long-acting intravitreal implant. Case studies with panel discussion.
Chairmen: Professor Quan Dong Nguyen, Byers Eye Institute, California, USA| 12:55 | Welcome and Introductions |
| Professor Quan Dong Nguyen | |
| 12:58 | Optimizing Treatment for Recurrent Non-infectious Uveitis: Evidence from PSV-FAi-001 and PSV-FAi-005 |
| Professor Carlos Pavesio | |
| 13:03 | Navigating Treatment Decisions in NIU-PS: A Traffic Light Approach with the 0.2 µg/day Fluocinolone Acetonide Intravitreal Implant |
| Professor Uwe Pleyer | |
| 13:08 | NIU-PS case 1 presentation |
| Ms Ilaria Testi | |
| 13:14 | NIU-PS case 2 presentation |
| Ms Sarah Touhami | |
| 13:20 | NIU-PS case 3 presentation |
| Mr Will Tucker | |
| 13:26 | NIU-PS case 4 presentation |
| speaker tbc | |
| 13:32 | NIU-PS case 5 presentation |
| speaker tbc | |
| 13:38 | Conclusions |
| Professor Quan Dong Nguyen | |
| 13:45 | END OF SYMPOSIUM |
Satellite Symposium by KODIAK Sciences Inc.
Friday, June 27, 2025 - 07:00-07:50 - Gavea B
Friday, June 27, 2025 - 07:00-07:50 - Gavea B
Title
Chairmen: ...| 07:00 | Title |
| speaker | |
| 07:00 | Title |
| speaker | |
| 07:00 | Title |
| speaker | |
| 13:45 | END OF SYMPOSIUM |
Satellite Symposium by PROVIANT Therapeutics
Friday, June 27, 2025 - 12:55-13:45 - Gavea B
Friday, June 27, 2025 - 12:55-13:45 - Gavea B
A Potential New Oral Therapy (JAK inhibitor) for Non-Infectious Uveitis: Results from Phase 2 Study (NEPTUNE) and Progress from Phase 3 Study (CLARITY)
hosted by Priovant Therapeutics
Chairmen: Mr Scott Jones - Proviant Therapeutics| 12:55 | Rationale for brepocitinib in NIU, results from Phase 2 study, progress on Phase 3 study |
| Prof. Quan Dong Nguyen, Stanford Byers Eye Institute | |
| 13:15 | Introduction to Priovant, background on brepocitinib (moderator) |
| Mr. Scott Jones, Priovant Therapeutics | |
| 13:25 | Panel of CLARITY Study Investigators |
| Moderated by Scott Jones | |
| 13:25 | Discussion of JAK inhibition in NIU, design and implementation of the Phase 3 study, and taking questions from the audience. |
| Dr Quan Nguyen, Stanford Byers Eye Institute, USA Dr Elisabetta Miserocchi, Universita Via-Salute San Raffaele, Italy Dr Ariel Schlaen, Hospital Universitario Austral, Argentina Dr Nima Ghadiri, Liverpool University Hospital NHS Foundation Trust, UK Scott Jones, Priovant Therapeutics, moderator |
|
| 13:45 | END OF SYMPOSIUM |
EXPO FLOORPLAN
The expo takes places on the 5th Floor in the Foyer - by the lecture rooms.
The expo takes places on the 5th Floor in the Foyer - by the lecture rooms.
THANK YOU SPONSORS
IOIS 2025 was made possible thanks to the support of the following companies:
IOIS 2025 was made possible thanks to the support of the following companies: